SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to represent SpaceX, with many warning it is a scam while others speculate on its connection to the company's long-rumored IPO. The community conversation is dominated by intense skepticism regarding unauthorized tokens, contrasted with broader market excitement surrounding SpaceX's expected public debut and its potential impact on space-sector stocks.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending as investors focus on its U.S.-based ISR production ramp-up, with community discussions highlighting its potential to capture rising demand from AI-driven data center power needs. The stock is seeing heavy attention amid a broader nuclear energy narrative, as market participants monitor institutional accumulation and upcoming earnings in anticipation of a potential sector-wide squeeze.

USDX is the crypto-backed native stablecoin of the Kava DeFi hub.

USDX Stablecoin

The USDX is currently a focal point for technical analysts utilizing Elliott Wave theory, with the community actively debating whether the index is consolidating within a corrective triangle or preparing for a broader trend shift. Traders are closely monitoring the dollar's interaction with key support and resistance levels while gauging how correlated moves in major pairs like the GBPUSD and USDJPY will influence the index's next structural move.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors weigh the company's aggressive AI and cloud infrastructure pivot against upcoming earnings and high-stakes geopolitical trade talks. While the community is split between bullish sentiment over long-term AI potential and skepticism surrounding recent earnings volatility, attention is heavily focused on whether institutional positioning will trigger a re-rating for the stock.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is drawing significant investor interest due to its pivot toward a vertically integrated U.S. supply chain for critical minerals and rare earth magnets, which community members view as a strategic hedge against international trade tensions. While some participants are wary of potential volatility and bot activity, the stock is currently trending on the back of news regarding infrastructure expansion and institutional investment, fueling speculation about its long-term role in domestic industrial independence.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors highlight its role as an AI-powered infrastructure project on the Base ecosystem, with community members actively discussing its long-term potential as an undervalued asset. The sentiment is fueled by consistent development updates from the team and strong ecosystem volume, leading many to hold through market volatility in anticipation of future price appreciation.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is currently trending due to the completed enrollment of its Phase 3 SENTRY trial for myelofibrosis, though community discussion remains deeply polarized by frustration over persistent financial instability and long-standing concerns regarding executive leadership. Investors are actively debating the potential for a clinical turnaround against the backdrop of an extended cash runway and the company's challenging historical performance.

Select Sector SPDR Trust (The) - State Street Industrial Select Sector SPDR ETF

Industrial Select Sector SPDR Fund

The Industrial Select Sector SPDR Fund (XLI) is seeing significant community focus as technical analysts leverage Elliott Wave strategies to identify and trade within high-probability reaction zones. While some investors are concerned about broader economic headwinds and sector rotation, others remain bullish, viewing current pullbacks as strategic entry points for long-term industrial exposure.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending as investors monitor institutional accumulation and signs of a potential short squeeze amid anticipation of profitability in the coming quarters. The community is actively discussing the drug's strong prescription growth and its long-term potential as an acquisition target for larger pharmaceutical firms.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is seeing significant community interest driven by its strategic acquisition of Covelya Group, which bolsters its subsea technology platform, and heightened geopolitical focus on critical underwater infrastructure protection. Investors are actively discussing the company's long-term defense sector role, its potential for major exchange uplisting, and strong revenue growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Do Not Ignore this Rally

The market is currently witnessing a rare phenomenon: a synchronized breakout across the small-cap and emerging growth sectors. While mega-cap tech grabs the headlines, the real alpha is being generated by innovators in energy, space, and biotech. As we head into the closing bell and the crucial after-hours session, momentum is building in names that are fundamentally shifting their industries. $INTC, $RXT, $BB, $TRAW, $XERI, $RDW

<ul class="summary-bullets"><li>Traws Pharma already develops antiviral drugs for influenza, H5N1 bird flu, and COVID-19.</li><li>Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50% in humans.</li><li>The World Health Organization said the outbreak is not expected to become a pandemic like COVID-19 because the virus spreads mainly through close personal contact.</li></ul>Shares of Traws Pharma (TRAW) jumped 30% in early trade on Friday after the biotech firm announced plans to advance potential clinical candidates for the treatment of hantavirus infections, as it looks to take on bigger vaccine makers like Moderna and Inovio.The latest intraday jump extends a strong run for <a href="https://stocktwits.com/symbol/TRAW">TRAW shares</a>, which had already climbed about 19% in May through Thursday’s close.<h2 class="st-heading-2">What Is Hantavirus?</h2>Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50% in humans. The latest fear comes amid an outbreak aboard the Dutch-flagged cruise ship Hondius, which has been linked to three deaths and several infections.The World Health Organization (WHO) said the outbreak is not expected to become a pandemic like COVID-19 because the virus spreads mainly through close personal contact. However, the agency warned that more cases could still emerge due to the disease’s incubation period, which can last up to six weeks.<h2 class="st-heading-2">TRAW Banks On Antiviral Experience</h2>Traws Pharma said its experience in developing antiviral drugs for illnesses such as influenza, H5N1 bird flu, and COVID-19 could help support the development of new treatments for hantavirus, which currently has no approved therapy for pulmonary disease.“Traws intends to move rapidly, using its established network of drug development and virus testing assets, to identify the optimal candidates for Hantaan virus treatment and, additionally, to access proprietary chemical libraries for homing in on the best potential treatments,” said C. David Pauza, chief scientific officer at Traws Pharma.<h2 class="st-heading-2">Retail Chatter Is Mixed On TRAW</h2>Retail sentiment for TRAW on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes on the platform jumped 820% over the past 24 hours.One user said the stock could see a 20x increase in value if a major outbreak occurs.<stembedurl>https://stocktwits.com/Dwarn2021/message/652709756</stembedurl>The stock has surged 90% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/artiva-artv-stock-gains-arthritis-therapy-update-300m-fund-raising/cZX2mO2ReX6">ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

A Hantavirus Update Has Sent This Nano-Cap Biotech Stock Surging Today – Here’s Why Retail Sees Potential 20x Gains

Traws Pharma, which develops antiviral drugs, said it plans to advance potential clinical candidates for the treatment of hantavirus infections.

TRAW Stock Gained 30% Today – What’s The Hantavirus Connection?

Equity

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

<ul class="summary-bullets"><li>The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.</li><li>Early data analysis supports Ratutrelvir’s favorable tolerability profile, faster symptom resolution, and lack of viral rebound events, the company said.</li><li>Traws is advancing Tivoxavir Marboxil as a potential once-monthly oral preventive treatment for seasonal flu.</li></ul>Shares of Traws Pharma, Inc. (TRAW) gained about 5% in premarket trading but slipped after the opening bell following the company’s announcement that it has completed enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer, used to treat mild-to-moderate COVID-19. Traws said that patients unable to take Paxlovid are often at greater risk of severe disease, and that Ratutrelvir may help address this unmet need as an alternative treatment option.Patients receiving Ratutrelvir were treated with a once-daily oral dose for 10 days, while those in the separate treatment arm received standard Paxlovid dosing for five days. According to the company, early data analysis supports Ratutrelvir’s favorable tolerability profile, faster symptom resolution, and lack of viral rebound events.“The combination of early and sustained symptom improvement, extended dosing duration, absence of viral rebound observed to date, and favorable tolerability supports the strategic hypothesis that Ratutrelvir may have utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID),” said Robert R. Redfield, Chief Medical Officer of Traws Pharma.<h2 class="st-heading-2">Influenza Treatment Update</h2>In addition to the COVID-19 program, Traws provided an update on Tivoxavir Marboxil, an investigational antiviral for influenza. The company is advancing the drug as a potential once-monthly oral preventive treatment for seasonal flu, expanding its pipeline of therapies targeting respiratory viral diseases.Meanwhile,&nbsp;retail sentiment for TRAW remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/TRAW_jpg_41217ff328.webp" alt="TRAW.jpg">The stock has rebounded sharply in 2026, with <a href="https://stocktwits.com/symbol/TRAW">TRAW</a> up more than 115% amid renewed buying interest.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mnkd-stock-jump-over-7-in-pre-market-today/cmy787FR4Wz">Why Did MNKD Stock Jump Over 7% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?

The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Traws Pharma shares surged more than 200% on Monday, reaching highs seen in June after the company announced significant progress in developing its investigational one-dose influenza therapy, tivoxavir marboxil, for H5N1 bird flu treatment.&nbsp;Trading volume skyrocketed to over 2,600 times the daily average.In laboratory studies, tivoxavir marboxil demonstrated efficacy against highly pathogenic H5N1 influenza isolates.&nbsp;Traws’ Chief Science Officer David Pauza highlighted preclinical results, showing complete survival and reduced lung virus levels in mice infected with human H5N1 isolated from a dairy worker exposed to infected cattle.&nbsp;CEO Werner Cautreels added that Phase 1 clinical trial data confirmed the therapy’s safety and tolerability.&nbsp;A Phase 2 study is planned for the first half of 2025, the company said.The announcement comes amid escalating concerns over H5N1’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/health/health-news/bird-flu-cases-spread-warning-signs-rcna185084">spread</a>.&nbsp;The U.S. has reported 64 infections since April, with dairy herds in 16 states affected.&nbsp;Last week, California declared a state of emergency after an uptick in cases among dairy cows, and Louisiana reported the country’s first severe human infection.Retail interest&nbsp;in Traws surged on Monday, making its stock one of the top three trending symbols on Stocktwits.&nbsp;Discussions on the platform were mixed, with some predicting a breakout above $20 — a level last seen in April — and others cautioning about a potential share offering due to the company’s tight financial position.&nbsp;<stembedurl>https://stocktwits.com/miraclehunter/message/597607177</stembedurl><stembedurl>https://stocktwits.com/MarketAce/message/597606552</stembedurl>As of the last quarter, Traws had $5.4 million in cash and $11 million in liabilities, according to data on Koyfin.In addition to tivoxavir marboxil, Traws Pharma’s pipeline includes ratutrelvir for COVID-19, targeting viral proteases, and investigational cancer therapies like narazaciclib and rigosertib, which focus on cell cycle proteins.Traws Pharma began trading on&nbsp;the Nasdaq in April following the acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics.&nbsp;Still, the stock remains down 24% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of chickens and a rooster at a farm as California declares a state of emergency to prevent a new public health crisis on Bird flu in Pescadero, California, United States on December 20, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars

The U.S. has reported H5N1 Bird Flu 64 infections since April, with dairy herds in 16 states affected. 

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

TRAW
Traws Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest TRAW News

TRAWTraws Pharma Inc.